Contemporary trial data and global registries consistently show that ambulatory patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event still carry residual risk of cardiovascular death and heart failure hospitalizations. These annual rates have been estimated to exceed 10%–20%, despite adherence to quadruple guideline-directed medical therapy (GDMT) and device support. This paradox of clinical stability on the surface, yet significant residual risk underneath, creates a critical blind spot in the management of chronic HFrEF. Recent data show that the addition of soluble guanylate cyclase (sGC) stimulators provides significant reductions in CV death and all-cause mortality, particularly in individuals with moderately elevated NT-proBNP (≤6,000 pg/mL). These findings are especially important because this population is far more common in routine cardiology practice and has historically been overlooked in discussions of additional therapy. Tune in to explore a case to better understand which patients can derive the most benefit from added therapy.